Targeting survival factors for ocular neovascularization
Targeting survival factors for ocular neovascularization
批准号:
7211882
负责人:
Peter A Campochiaro
金额:
$40.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2012-03-31
关键词:
AblationAcuteAddressAdultAgeAge related macular degenerationAngiopoietin-1Angiopoietin-2ApoptosisAreaBenefits and RisksBlindnessBlood VesselsBruch&aposs basal membrane structureCXCR4 ReceptorsCell ProliferationCellsCessation of lifeChemotactic FactorsChimeric ProteinsChoroidChoroidal NeovascularizationChronicClinical TrialsCombined Modality TherapyCoupledDevelopmentDiabetic RetinopathyDisease regressionEndothelial CellsExtracellular MatrixExtravasationFamily memberFc ImmunoglobulinsGoalsGrantITGAM geneImmunoglobulin GImmunohistochemistryInfiltrationLaboratoriesLeadLocalizedLong-Term EffectsMolecularMononuclearMusMyeloid CellsNeuronsPatientsPericytesPhotoreceptorsPlatelet-Derived Growth FactorPlatelet-Derived Growth Factor ReceptorPlatelet-Derived Growth Factor beta ReceptorPlayProcessProto-Oncogene Proteins c-sisPublic HealthRelative (related person)Research PersonnelRetinaRetinalRetinal DiseasesReverse Transcriptase Polymerase Chain ReactionRoleRuptureSignal PathwaySignal TransductionSiteSourceStimulusStromal Cell-Derived Factor 1StructureStructure of retinal pigment epitheliumTestingTetanus Helper PeptideTherapeuticTimeTissuesTransgenic MiceTreatment ProtocolsVascular Endothelial CellVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsVascular PermeabilitiesWNT Signaling Pathwaybasemacrophagemonocyteneovascularizationnovel therapeuticsocular neovascularizationprogramsreceptorreceptor couplingretina blood vessel structureretinal neurontherapeutic targettherapy developmentvascular bed
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: Vascular endothelial cells participating in neovascularization (NV) depend upon survival factors. If the survival factors are withdrawn or blocked, the endothelial cells undergo apoptosis and the NV regresses. Thus, identifying survival factors and finding ways to block them is a useful strategy for development of treatments for established NV. Right after sprouting, most types of NV tend to be very dependent upon vascular endothelial growth factor (VEGF) for survival, but over time the vessels mature and as part of the maturation process they acquire additional survival signals from extracellular matrix (ECM) and perivascular cells (pericytes). Defining these survival signals is an important goal. Two candidates are angiopoietin 1 (Ang1) acting through the Tie receptors on endothelial cells and platelet-derived growth factor-B (PDGF-B) acting through PDGF beta receptors on pericytes. Completely mature vessels tend to be less dependent upon VEGF, Ang1, and PDGF-B than new vessels, but this is a relative difference. For instance some normal vascular beds in adults, usually those that contain fenestrated vessels, still contain vessels that regress when VEGF is blocked. Also, while these molecules primarily target vascular cells they may also have survival-promoting effects for some neurons. Therefore, in order to target these survival signals to develop treatments for ocular NV, it is critical to determine the effect of blocking them on the normal retina and choroid as well as on ocular NV. We propose to do this using transgenic mice with inducible expression of potent blockers for each of the survival signals; soluble VEGF receptor 1 coupled to IgG Fc (VEGFtrap) to block VEGF, Ang2 to block Ang1, and soluble PDGF beta receptor coupled to IgG Fc (PDGFtrap) to block PDGF-B. The effect of expressing each of these antagonists alone and together will be examined both on
choroidal NV that has been present for various amounts of time, and on the normal retina and choroid.
Macrophages are another rich source of both survival and death signals for NV; therefore, we will use mice in which macrophages are ablated to determine their role in formation and regression of VEGF-induced ocular NV. This study addresses important public health problems, because it could lead to new treatments for established ocular NV which occurs in age-related macular degeneration and diabetic retinopathy, the most common causes of severe vision loss in the US.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
-
批准号:10333382
-
项目类别:
-
资助金额:$34.24万
-
财政年份:2022
-
负责人:Peter A Campochiaro
-
依托单位:
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
-
批准号:10593947
-
项目类别:
-
资助金额:$42.8万
-
财政年份:2022
-
负责人:Peter A Campochiaro
-
依托单位:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
-
批准号:10557124
-
项目类别:
-
资助金额:$59.89万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
-
批准号:10549354
-
项目类别:
-
资助金额:$40.94万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
-
批准号:10326840
-
项目类别:
-
资助金额:$39.71万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
-
批准号:10093050
-
项目类别:
-
资助金额:$58.1万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action
-
批准号:10361561
-
项目类别:
-
资助金额:$39.71万
-
财政年份:2019
-
负责人:Peter A Campochiaro
-
依托单位:
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases
-
批准号:9317491
-
项目类别:
-
资助金额:$20.44万
-
财政年份:2016
-
负责人:Peter A Campochiaro
-
依托单位:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
-
批准号:8964295
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2015
-
负责人:Peter A Campochiaro
-
依托单位:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
-
批准号:9256464
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2015
-
负责人:Peter A Campochiaro
-
依托单位:
Novel Biodegradable Injectable Rod for Improved AMD Therapy
-
批准号:8647445
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:Peter A Campochiaro
-
依托单位:
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
-
批准号:6342681
-
项目类别:
-
资助金额:$27.44万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
-
批准号:2761264
-
项目类别:
-
资助金额:$27.38万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6622273
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6721137
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6840788
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Targeting survival factors for ocular neovascularization
-
批准号:7587922
-
项目类别:
-
资助金额:$39.4万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
New Treatments of Ocular Neovascularization and Macular Edema
-
批准号:8441484
-
项目类别:
-
资助金额:$38.48万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6444529
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Targeting survival factors for ocular neovascularization
-
批准号:7415013
-
项目类别:
-
资助金额:$38.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
海外基金